[Therapeutic monitoring of teicoplanin in a severely burned patient].
The authors report the study of the kinetics in serum and urine and the clinical safety of a high dose of teicoplanin administered in a 19 year-old patient with major burns (60% of body surface area, the half of which consisting of third-degree burns and UBS at 150) and S aureus meticillin-resistant infection. At day 1, he was given two loading infusions of 12 mg.kg-1 teicoplanin followed by 12 mg.kg-1 per day of treatment. At all times, Cmin concentrations were below the limit value of 8 mg.mL-1. Therefore the therapeutic regimen was increased on several occasions. On days 5, 8 and 15, Cmin were measured by FPIA. Pharmacokinetic analysis was performed at day 16, (i.e., 20 mg.kg-1) and urine was also collected over at least 12 hours. At day 16, serum and urine samples were assayed by HPLC. Data were analyzed with a noncompartmental method. The duration of treatment was 20 days and no adverse events were noted. Bacteriological tests performed at the end of treatment demonstrated the elimination of the agent responsible over the infection. While pharmacokinetics were not assessed at plateau, Cmin remained very low. Vss was similar to values obtained in healthy subjects while total clearance was increased. This phenomenon was explained by the increase of total clearance and a nonrenal translesional diffusion suggested by the body surface area affected by third-degree burns. Finally, the cost of increasing doses of teicoplanin must be taken in account.
Lesne-Hulin
A
A
Service de pharmacie clinique, hôpital Necker-Enfants Malades, Paris, France.
Bourget
P
P
Le Bever
H
H
Ainaud
P
P
Carsin
H
H
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001830:Body Surface Area; D002056:Burns / Q000150:complications / Q000378:metabolism*; D002058:Burns, Electric / Q000150:complications / Q000378:metabolism; D004058:Diffusion; D005122:Exudates and Transudates / Q000378:metabolism; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology; D017334:Teicoplanin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D000900:Anti-Bacterial Agents; D017334:Teicoplanin